Back to top
more

Merit Medical Systems (MMSI)

(Delayed Data from NSDQ)

$94.35 USD

94.35
239,975

+0.59 (0.63%)

Updated Oct 11, 2024 04:00 PM ET

After-Market: $94.34 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (186 out of 250)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

3 Reasons to Retain Masimo (MASI) Stock in Your Portfolio

Investors continue to be optimistic about Masimo (MASI) due to its focus on patient monitoring.

Alcon (ALC) Vision Care Sales Robust, Margin Pressure Persists

For Alcon (ALC), in terms of end market, Surgical global cataract procedure growth varies significantly by region.

Globus Medical's (GMED) REFLECT Correction System Gets FDA Nod

Globus Medical's (GMED) REFLECT is intended to treat young children with progressive scoliosis, while preserving motion, stability and future modulated growth.

Here's Why Investors Should Retain LabCorp (LH) Stock for Now

Investors are optimistic about LabCorp (LH) on strategic partnerships and upbeat guidance.

Shockwave Medical (SWAV) Launches IVL Catheter in Select Markets

Shockwave Medical's (SWAV) latest commercial availability and the patient enrollment in its study are expected to serve a wider patient pool.

Abbott's (ABT) New Pact to Advance Clinical Trials Diversity

Abbott's (ABT) latest additions to Diversity in Clinical Trials effort expand upon the alliances, awards and the emphasis on diverse participation in its own clinical trials.

Here's Why You Should Retain Veeva Systems (VEEV) Stock Now

Veeva Systems' (VEEV) strong product portfolio raises optimism about the stock.

National Vision (EYE) Q1 Earnings Top Estimates, Margins Down

National Vision's (EYE) Q1 net revenues are positively impacted by the timing of unearned revenue.

Here's Why You Should Retain Patterson Companies (PDCO) Stock Now

Investors remain optimistic about Patterson Companies (PDCO) on the back of its broad product line.

NextGen (NXGN) Behavioral Health Suite to Focus on Mental Health

NextGen's (NXGN) Behavioral Health Suite is expected to offer better access to care and improve patient outcomes.

Revvity's (PKI) Q1 Earnings Top, '23 View Below Expectations

Revvity's (PKI) first-quarter results reflect the impact of transition following divestment of AES business. While earnings outpace estimates, sales miss the same.

Fresenius Medical (FMS) Q1 Earnings and Revenues Beat Estimates

Fresenius Medical's (FMS) first-quarter revenues benefit from strong performances across all segments, especially the North America and Asia-Pacific regions. However, rising costs hurt margins.

Masimo (MASI) Q1 Earnings Surpass Estimates, Margins Down

Masimo's (MASI) robust product shipments and continued strength in its healthcare business drive its Q1 sales.

DaVita (DVA) Tops Q1 Earnings Estimates, Ups FY23 EPS View

DaVita's (DVA) robust revenues in both segments drive its first-quarter performance.

Shockwave Medical (SWAV) Q1 Earnings Top, Revenues Surge Y/Y

Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion on the back of strong demand and new launches.

McKesson (MCK) Q4 Earnings Beat Estimates, U.S. Sales Strong

McKesson's (MCK) fiscal fourth-quarter 2023 results benefit from growth in the United States. Divestment hurt the International segment.

OPKO Health (OPK) Q1 Earnings and Revenues Top Estimates

Despite OPKO Health's (OPK) robust RAYALDEE sales and strength in the Pharmaceuticals segment, its overall first-quarter results reflect soft performances.

QuidelOrtho (QDEL) Q1 Earnings Top Estimates, FY23 View Revised

Despite solid performances by the Labs segment and China region, QuidelOrtho (QDEL) reports soft overall top-line results in first-quarter 2023.

BD (BDX) Q2 Earnings Surpass Estimates, FY23 View Revised

BD's (BDX) overall top line benefits from revenue growth in the majority of its segments and both geographic regions in the fiscal second quarter.

PacBio (PACB) Tops on Q1 Earnings, Raises FY23 Revenue View

PacBio (PACB) witnesses strong revenue growth in the first quarter. This is partly aided by customers' product transition to the Revio system.

Inspire Medical (INSP) Q1 Earnings & Revenues Top Estimates

Inspire Medical's (INSP) both geographic regions witness strong revenue growth in the first quarter.

Ecolab (ECL) Q1 Earnings & Revenues Beat, Margins Up

Ecolab's (ECL) robust performance across all segments drives its Q1 sales despite business challenges.

Avantor (AVTR) Q1 Earnings Surpass Estimates, Margins Down

Despite Avantor's (AVTR) strength in bioproduction and strength in Applied Technologies and Advanced Materials end markets, it reports an overall soft Q1 performance.

Merit Medical (MMSI) Tops Q1 Earnings Estimates, Ups FY23 View

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the first quarter.